BRPI0607529B8 - compostos azol e composições farmacêuticas compreendendo os mesmos - Google Patents
compostos azol e composições farmacêuticas compreendendo os mesmosInfo
- Publication number
- BRPI0607529B8 BRPI0607529B8 BRPI0607529A BRPI0607529A BRPI0607529B8 BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8 BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8
- Authority
- BR
- Brazil
- Prior art keywords
- azole compounds
- same
- pharmaceutical compositions
- stroke
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| US60/674,530 | 2005-04-22 | ||
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0607529A2 BRPI0607529A2 (pt) | 2009-09-15 |
| BRPI0607529B1 BRPI0607529B1 (pt) | 2021-05-18 |
| BRPI0607529B8 true BRPI0607529B8 (pt) | 2021-05-25 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607529A BRPI0607529B8 (pt) | 2005-04-22 | 2006-04-21 | compostos azol e composições farmacêuticas compreendendo os mesmos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (enExample) |
| EP (1) | EP1879873B1 (enExample) |
| JP (1) | JP5035238B2 (enExample) |
| KR (1) | KR101286499B1 (enExample) |
| CN (1) | CN101228138B (enExample) |
| AR (1) | AR053065A1 (enExample) |
| AU (1) | AU2006237798B2 (enExample) |
| BE (1) | BE2021C524I2 (enExample) |
| BR (1) | BRPI0607529B8 (enExample) |
| CA (1) | CA2606258C (enExample) |
| DK (1) | DK1879873T3 (enExample) |
| ES (1) | ES2441765T3 (enExample) |
| FI (1) | FIC20210018I1 (enExample) |
| MX (1) | MX2007013197A (enExample) |
| MY (1) | MY148589A (enExample) |
| NL (1) | NL301106I2 (enExample) |
| PL (1) | PL1879873T3 (enExample) |
| PT (1) | PT1879873E (enExample) |
| RU (1) | RU2418792C2 (enExample) |
| TW (1) | TWI398249B (enExample) |
| WO (1) | WO2006112685A1 (enExample) |
| ZA (1) | ZA200709994B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| KR101468553B1 (ko) | 2007-05-14 | 2014-12-09 | 에스케이바이오팜 주식회사 | 신규 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물,이를 함유하는 약제학적 조성물 및 상기 화합물 투여에의한 통증, 불안증 및 우울증 치료 방법 |
| JP5444535B2 (ja) | 2007-06-05 | 2014-03-19 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン |
| CN102026988B (zh) * | 2008-06-05 | 2013-07-03 | 爱思开生物制药株式会社 | 3-取代的丙胺化合物 |
| ES2541590T3 (es) * | 2009-06-22 | 2015-07-22 | Sk Biopharmaceuticals Co., Ltd. | Método para la preparación de éster (R)-1-aril-2-tetrazolil-etílico de ácido carbámico |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| CN102781436B (zh) | 2009-11-06 | 2014-01-08 | 爱思开生物制药株式会社 | 纤维肌痛综合征的治疗方法 |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| PT2800738T (pt) * | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| ES2901427T3 (es) * | 2016-12-14 | 2022-03-22 | Sk Biopharmaceuticals Co Ltd | Preparación líquida parenteral que comprende un compuesto de carbamato |
| KR102635931B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| JP7090616B2 (ja) * | 2016-12-14 | 2022-06-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む口腔内崩壊錠 |
| WO2018111006A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| KR102635941B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| WO2018111008A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| KR102739607B1 (ko) | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 |
| ES2973111T3 (es) * | 2017-11-14 | 2024-06-18 | Sk Biopharmaceuticals Co Ltd | Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio |
| MX2020004974A (es) * | 2017-11-14 | 2020-08-24 | Sk Biopharmaceuticals Co Ltd | Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett. |
| ES2982316T3 (es) * | 2017-11-14 | 2024-10-15 | Sk Biopharmaceuticals Co Ltd | Uso de un compuesto de carbamato para prevenir, aliviar o tratar las crisis de ausencia o la epilepsia que muestra crisis de ausencia |
| US11389429B2 (en) | 2017-11-14 | 2022-07-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating myotonia |
| ES3027977T3 (en) * | 2017-11-14 | 2025-06-17 | Sk Biopharmaceuticals Co Ltd | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| ES2978226T3 (es) * | 2018-09-21 | 2024-09-09 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático |
| KR20210047887A (ko) * | 2018-09-21 | 2021-04-30 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| CN112912076B (zh) * | 2018-10-19 | 2024-07-16 | 爱思开生物制药株式会社 | 氨基甲酸酯化合物用于预防、缓解或治疗糖尿病性周围神经病变或化疗诱发性周围神经病变的用途 |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| EP4062906A4 (en) * | 2019-11-22 | 2024-01-03 | SK Biopharmaceuticals Co., Ltd. | ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMAT COMPOUND AND PROCESS FOR PRODUCTION THEREOF |
| JP2023536341A (ja) * | 2020-08-06 | 2023-08-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む経口用固形製剤及びその製造方法 |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| RU2117664C1 (ru) * | 1991-08-22 | 1998-08-20 | Варнер-Ламберт Компани | Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли |
| RU2298552C2 (ru) * | 2001-06-25 | 2007-05-10 | СК Корпорейшн | Карбаматы 2-гетероциклил-1,2-этандиолов |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607529B8 (pt) | compostos azol e composições farmacêuticas compreendendo os mesmos | |
| WO2009035473A3 (en) | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders | |
| BRPI0918868B8 (pt) | compostos moduladores do receptor de nmda e composições compreendendo os mesmos | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| WO2007137247A3 (en) | Treatment for depressive disorders | |
| BR112014009851A2 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
| DK1656122T4 (da) | Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| UA110199C2 (xx) | Тверда дисперсія рифаксиміну | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| BRPI0712206A2 (pt) | tratamento do agonista de melatonina | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| WO2008024371A3 (en) | Multimediator transporter inhibitors for use in treatment of central nervous system disorders | |
| BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
| EP4086249A3 (en) | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
| ATE507214T1 (de) | Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität | |
| BRPI0410837A (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição | |
| TW200716204A (en) | Pharmaceutical composition | |
| PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| BRPI0413132A (pt) | composições e compostos bicìclicos como inibidores de pdf | |
| ATE445633T1 (de) | Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |